Halozyme Therapeutics HALO Sale of investments
Sale of investments at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's sale of investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's sale of investments?
- Halozyme Therapeutics (HALO) reported sale of investments of $9M in Q1 2026.
- How has Halozyme Therapeutics's sale of investments changed year-over-year?
- Halozyme Therapeutics's sale of investments decreased by 82.1% year-over-year, from $50.17M to $9M.
- What does sale of investments mean?
- This represents cash inflows from the sale of marketable securities, such as corporate bonds or government debt, classified as available-for-sale. It reflects the company's active management of its liquid investment portfolio.